Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  HIV Infection

  Free Subscription


Articles published in Antivir Ther

Retrieve available abstracts of 30 articles:
HTML format
Text format



Single Articles


    October 2018
  1. SPINNER CD, Schulz S, Bauer U, Schneider J, et al
    Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: The TAF-IR Study.
    Antivir Ther. 2018 Oct 3. doi: 10.3851/IMP3271.
    PubMed     Text format     Abstract available


  2. CICCULLO A, Baldin G, Capetti A, Rusconi S, et al
    A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Antivir Ther. 2018 Oct 2. doi: 10.3851/IMP3270.
    PubMed     Text format     Abstract available


    September 2018
  3. HIRANSUTHIKUL A, Thammajaruk N, Techatanawat I, Karachot B, et al
    Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
    Antivir Ther. 2018 Sep 28. doi: 10.3851/IMP3267.
    PubMed     Text format     Abstract available


  4. HAVENS PL, Long D, Schuster GU, Gordon CM, et al
    Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Antivir Ther. 2018 Sep 27. doi: 10.3851/IMP3269.
    PubMed     Text format     Abstract available


  5. LADAK F, Socias E, Nolan S, Dong H, et al
    Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Antivir Ther. 2018 Sep 19. doi: 10.3851/IMP3265.
    PubMed     Text format     Abstract available


  6. VEGA AD, Hynicka LM, Claeys K, Chua JV, et al
    Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.
    Antivir Ther. 2018 Sep 7. doi: 10.3851/IMP3263.
    PubMed     Text format     Abstract available


    August 2018
  7. MEE TC, Aepfelbacher J, Krakora R, Chairez C, et al
    Carotid magnetic resonance imaging in persons living with HIV and 10-year atherosclerotic cardiovascular disease risk score.
    Antivir Ther. 2018 Aug 8. doi: 10.3851/IMP3258.
    PubMed     Text format     Abstract available


    July 2018
  8. OJHA RP, MacDonald BR, Chu TC, Fasanmi EO, et al
    Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection.
    Antivir Ther. 2018 Jul 3. doi: 10.3851/IMP3249.
    PubMed     Text format     Abstract available


    May 2018
  9. WEBER MD, Andrews E, Prince HA, Sykes C, et al
    Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
    Antivir Ther. 2018 May 1. doi: 10.3851/IMP3236.
    PubMed     Text format     Abstract available


    March 2018
  10. MERLINI E, Galli L, Tincati C, Cannizzo ES, et al
    Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy.
    Antivir Ther. 2018 Mar 28. doi: 10.3851/IMP3234.
    PubMed     Text format    


  11. MERLINI E, Galli L, Tincati C, Cannizzo ES, et al
    Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy.
    Antivir Ther. 2018 Mar 28. doi: 10.3851/IMP3239.
    PubMed     Text format    


  12. TEERAANANCHAI S, Kerr SJ, Ruxrungtham K, Avihingsanon A, et al
    Loss to follow-up and associated factors of patients through the National AIDS Program in Thailand.
    Antivir Ther. 2018 Mar 27. doi: 10.3851/IMP3233.
    PubMed     Text format     Abstract available


  13. VAN DAM PM, van Geffen MW, Havenith TR, Posthouwer D, et al
    Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
    Antivir Ther. 2018 Mar 13. doi: 10.3851/IMP3229.
    PubMed     Text format     Abstract available


    February 2018
  14. BENGTSON AM, Pence BW, Eaton EF, Edwards JK, et al
    Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.
    Antivir Ther. 2018 Feb 9. doi: 10.3851/IMP3223.
    PubMed     Text format     Abstract available


    January 2018
  15. BIGLIANO P, Calcagno A, Lucchini A, Audagnotto S, et al
    The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
    Antivir Ther. 2018 Jan 26. doi: 10.3851/IMP3221.
    PubMed     Text format     Abstract available


  16. FIORENTINO M, Suzan-Monti M, Vilotitch A, Sagaon-Teyssier L, et al
    Renunciation of health care by people living with HIV in France is still associated with discrimination in health care services and social insecurity - results from the ANRS VESPA2 survey.
    Antivir Ther. 2018 Jan 23. doi: 10.3851/IMP3220.
    PubMed     Text format     Abstract available


  17. PETERS L, Mocroft A, Grint D, Moreno S, et al
    Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
    Antivir Ther. 2018 Jan 5. doi: 10.3851/IMP3218.
    PubMed     Text format     Abstract available


    November 2017
  18. FALUTZ J
    Frailty: is thy name.....universal? Evolving challenges of managing effectively treated older people living with HIV.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3211.
    PubMed     Text format     Abstract available


  19. VENUTO CS, Lim J, Messing S, Hunt PW, et al
    Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3209.
    PubMed     Text format     Abstract available


  20. PATEL RR, Presti R, Harrison LC, Powderly WG, et al
    Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.
    Antivir Ther. 2017 Nov 23. doi: 10.3851/IMP3208.
    PubMed     Text format     Abstract available


    October 2017
  21. MORTIER V, Vancoillie L, Dauwe K, Staelens D, et al
    Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays.
    Antivir Ther. 2017 Oct 24. doi: 10.3851/IMP3203.
    PubMed     Text format     Abstract available


  22. BINDA F, Monge E, Simonetti FR, Zanchetta N, et al
    Primary HIV infection in patients with acute hepatitis B: a report of two cases.
    Antivir Ther. 2017 Oct 12. doi: 10.3851/IMP3201.
    PubMed     Text format     Abstract available


  23. HOPPE A, Giuliano M, Lugemwa A, Thompson JA, et al
    HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
    Antivir Ther. 2017 Oct 11. doi: 10.3851/IMP3200.
    PubMed     Text format     Abstract available


  24. ECKARD AR, O'Riordan MA, Rosebush JC, Lee ST, et al
    Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3199.
    PubMed     Text format     Abstract available


  25. JANTARABENJAKUL W, Anugulruengkitt S, Kasipong N, Thammajaruk N, et al
    Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198.
    PubMed     Text format     Abstract available


    September 2017
  26. SANTORO MM, Di Carlo D, Armenia D, Zaccarelli M, et al
    Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
    Antivir Ther. 2017 Sep 22. doi: 10.3851/IMP3197.
    PubMed     Text format     Abstract available


  27. MARTINEZ-VEGA R, De La Mata NL, Kumarasamy N, Ly PS, et al
    Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3194.
    PubMed     Text format     Abstract available


  28. SHARMA A, Hoover DR, Shi Q, Holman S, et al
    Longitudinal study of falls among HIV-infected and uninfected women: the role of cognition.
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3195.
    PubMed     Text format     Abstract available


  29. SRINIVASA S, Lu MT, Fitch KV, Hallett TR, et al
    Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV.
    Antivir Ther. 2017 Sep 20. doi: 10.3851/IMP3193.
    PubMed     Text format     Abstract available


    January 2017

  30. 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2017;22.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: